lymphocytes

[Harpoon Therapeutics, Inc.] Harpoon Therapeutics, Inc. announced that the US FDA has granted Orphan Drug Designation for HPN328, a delta like ligand 3- targeting TriTAC®, for the treatment of SCLC.

[Scientific Reports] Researchers investigated the epithelial cell response to B. pertussis infection in primary human airway epithelium differentiated at air–liquid interface.

[Basic Research in Cardiology] Researchers established an in vitro iPSC model of anthracycline-induced cardiotoxicity (ACT) from patients with an aggressive form of B-cell lymphoma and examined whether doxorubicin-treated ACT-iPSC cardiomyocytes could recapitulate the clinical features exhibited by patients.

[Alchemab Therapeutics] Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies in neurodegeneration and oncology, announced an extension of its collaboration with Medicines Discovery Catapult, a national facility enabling the UK’s community to accelerate innovative drug discovery.

[International Immunopharmacology] The authors observed that high-dose radiation remarkably increased the enrichment of stem cell-like CD8+ T cells.

[European Heart Journal] Scientists discuss the pertinent cardiovascular risks of the growing field of CAR-T cell therapy for today’s cardiologists, including incidence, characteristics, and treatment options, and will conclude with an integrated management algorithm.